SCHEMBL2931749

SCHEMBL2931749

CC(C)(C)OC(=O)N1CCC(Cn2cc3c(-c4ccc(F)cc4)c(-c4ccncc4)c(-c4ccc(F)cc4)nc3n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.43
JAK2 O60674 1/20 0.41
JAK3 P52333 1/20 0.41
PTK2 Q05397 1/20 0.41
GRIA1 P42261 1/20 0.41
KCNH2 Q12809 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
NAMPT P43490 1/20 0.40
MMP13 P45452 1/20 0.40
BTK Q06187 1/20 0.39
MERTK Q12866 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
ENPP2 Q13822 1/20 0.38
DNMT3A Q9Y6K1 1/20 0.38
TGFBR1 P36897 1/20 0.38
SLC34A1 Q06495 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931587 0.93 GPR119 (0.43) GPR119JAK2JAK3PTK2GRIA1
SCHEMBL2925845 0.87 GPR119 (0.41) GPR119JAK2JAK3PTK2GRIA1
SCHEMBL2925785 0.86 NAMPT (0.41) GPR119JAK2JAK3PTK2GRIA1
SCHEMBL2927906 0.86 SQOR (0.43) GPR119GRIA1KCNH2MAPK11MAPK14
SCHEMBL2925081 0.86 GPR119 (0.45) GPR119JAK2JAK3PTK2GRIA1
SCHEMBL2927353 0.85 SQOR (0.42) GPR119GRIA1KCNH2MAPK11MAPK14
SCHEMBL2930758 0.83 GPR119 (0.44) GPR119JAK2JAK3PTK2GRIA1
SCHEMBL1385787 0.80 RIPK3 (0.48) MAPK11MAPK14MERTK
SCHEMBL2932078 0.79 GPR119 (0.44) GPR119JAK2JAK3PTK2GRIA1
SCHEMBL2926287 0.79 NPY5R (0.41) KCNH2MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 GPR119 1784/4885JAK2 245/4885JAK3 558/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 GPR119 2008/4885JAK2 107/4885JAK3 361/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 GPR119 2008/4885JAK2 107/4885JAK3 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.